These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 31279301)
1. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301 [TBL] [Abstract][Full Text] [Related]
2. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437 [TBL] [Abstract][Full Text] [Related]
4. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897 [TBL] [Abstract][Full Text] [Related]
5. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890 [TBL] [Abstract][Full Text] [Related]
6. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study. Bergqvist M; Christensen HN; Wiklund F; Bergström S Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ Med Oncol; 2014 Aug; 31(8):119. PubMed ID: 25023055 [TBL] [Abstract][Full Text] [Related]
8. De novo Hepatitis B Virus Reactivation during Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer. Horibe R; Yokota M; Uemura K; Hashimoto M; Kawagishi N; Nishiyama K Intern Med; 2024 Jun; 63(12):1797-1800. PubMed ID: 37926534 [TBL] [Abstract][Full Text] [Related]
9. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239 [TBL] [Abstract][Full Text] [Related]
10. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand. Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868 [TBL] [Abstract][Full Text] [Related]
13. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer. Zhu YJ; Qu X; Zhan DD; Chen HH; Li HP; Liu LR; Chen X; Liu YH; Li Y; Bai JP; Ye S; Zhang HB Clin Lung Cancer; 2021 Jan; 22(1):e98-e111. PubMed ID: 33067127 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
16. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630 [TBL] [Abstract][Full Text] [Related]
17. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626 [TBL] [Abstract][Full Text] [Related]
18. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915 [TBL] [Abstract][Full Text] [Related]
19. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646 [TBL] [Abstract][Full Text] [Related]
20. Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area. Hirano R; Uchino J; Ueno M; Fujita M; Watanabe K Asian Pac J Cancer Prev; 2016; 17(2):785-9. PubMed ID: 26925681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]